Critical review of cancer risk associated with angiotensin receptor blocker therapy

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 741-747

  Wuerzner, Grégoire ^a   Burnier, Michel ^a   Waeber, Bernard ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiotensin receptor blocker; Cancer; Hypertension; Meta analyses

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST;

CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); OBESITY; PHYSIOLOGY; REVIEW; RISK FACTOR;

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONISTS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; META-ANALYSIS AS TOPIC; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OBESITY; RECEPTORS, ANGIOTENSIN; RISK FACTORS;

EID: 84861702752     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S13552     Document Type: Review

References (70)

1. Committee for Medicinal Products for Human Use, European Medicines Agency. Reflection Paper on Benefit-Risk Assessment Methods in the Context of the Evaluation of Marketing Authorization Applications of Medicinal Products for Human Use. London: European Medicines Agency; 2008. Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/Regulatory_and_procedural_guideline/2010/01/ WC500069634.pdf. Accessed March 19, 2008.
2. Hughes DA, Bayoumi AM, Pirmohamed M. Current assessment of risk-benefit by regulators: is it time to introduce decision analyses? Clin Pharmacol Ther. 2007;82(2):123-127.
3. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-1535.
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
5. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009;3:CD001841.
6. Heinonen OP, Shapiro S, Tuominen L, Turunen MI. Reserpine use in relation to breast cancer. Lancet. 1974;2(7882):675-677.
7. Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol. 1999;83(7): 1090-1093.
8. McLaughlin JK, Chow WH, Mandel JS, et al. International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer. 1995;63(2):216-221.
9. Pahor M, Guralnik JM, Fer rucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 1996;348(9026):493-497.
10. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med. 1992;327(10):685-691.
11. Coleman CI, Baker WL, Kluger J, White CM. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta analysis of randomized controlled trials. J Hypertens. 2008;26(4):622-629.
12. Grossman E, Messerli FH. Long-term safety of antihypertensive therapy. Prog Cardiovasc Dis. 2006;49(1):16-25.
13. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J. 2001;22(15):1343-1352.
14. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensinreceptor blockade and risk of cancer: meta analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627-636.
15. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
16. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354(16):1685-1697.
17. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359(12): 1225-1237.
18. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174-1183.
19. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559.
20. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-1675.
21. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360(9335):752-760.
22. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-1906.
23. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759-766.
24. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12(1):65-82.
25. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138(7):542-549.
26. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
27. Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360(16):1606-1617.
28. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772-776.
29. Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol. 2007;18(6):1889-1898.
30. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031.
31. Kasanuki H, Hagiwara N, Hosoda S, et al. Angiotensin II receptor blocker-based vs non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J. 2009;30(10):1203-1212.
32. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21(8):1563-1574.
33. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767-771.
34. Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbiditymortality study. Lancet. 2007;369(9571):1431-1439.
35. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870-878.
36. Sawada T, Yamada H, Dahlof B, Matsubara H. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J. 2009;30(20):2461-2469.
37. Suzuki H, Kanno Y. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res. 2005;28(4):307-314.
38. Suzuki H, Kanno Y, Sugahara S, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008; 52(3):501-506.
39. Zile MR, Gaasch WH, Anand IS, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010;121(12):1393-1405.
40. Teo KK, Sleight P, Gao P, et al. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29(4):623-635.
41. McMurray JJ, Holman RR, Rutten GEHM, Califf RM. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med. 2010;362(16):1477-1490.
42. Yusuf S, Healey JS, Pogue J, et al. Irbesartan in Patients with Atrial Fibrillation. N Engl J Med. 2011;364(10):928-938.
43. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372(9647):1394-1402.
44. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875-886.
45. Sjolie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372(9647):1385-1393.
46. Grossman E, Goldbourt U. Meta analyses of antihypertensive therapy: Are some of them misleading? Curr Hypertens Rep. 2001;3(5):381-386.
47. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998; 352(9123):179-184.
48. Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens. 2009;23(10):623-635.
49. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab. 2005;16(7):293-299.
50. Willis LM, El-Remessy AB, Somanath PR, Deremer DL, Fagan SC. Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin Sci (Lond). 2011;120(8):307-319.
51. Imai N, Hashimoto T, Kihara M, et al. Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest. 2007;87(2):189-198.
52. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res. 2006; 12(9):2888-2893.
53. Kosaka T, Miyajima A, Takayama E, et al. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate. 2007;67(1):41-49.
54. Otake AH, Mattar AL, Freitas HC, et al. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer Chemother Pharmacol. 2010;66(1): 79-87.
55. Kosaka T, Miyajima A, Shirotake S, et al. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer. Prostate. 2010;70(2): 162-169.
56. Clere N, Corre I, Faure S, et al. Def iciency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer. 2010;127(10): 2279-2291.
57. Walther T, Menrad A, Orzechowski HD, Siemeister G, Paul M, Schirner M. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J. 2003;17(14):2061-2067.
58. Forder JP, Munzenmaier DH, Greene AS. Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat. Am J Physiol Heart Circ Physiol. 2005;288(4):H1989-H1996.
59. Kozak A, Ergul A, El-Remessy AB, et al. Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. Stroke. 2009;40(5):1870-1876.
60. Buck C, Donner A. Cancer incidence in hypertensives. Cancer. 1987;59(7):1386-1390.
61. Raynor WJ Jr, Shekelle RB, Rossof AH, Maliza C, Paul O. High blood pressure and 17-year cancer mortality in the Western Electric Health Study. Am J Epidemiol. 1981;113(4):371-377.
62. Dyer AR, Stamler J, Berkson DM, Lindberg HA, Stevens E. High blood-pressure: a risk factor for cancer mortality? Lancet. 1975;1(7915):1051-1056.
63. Khaw KT, Barrett-Connor E. Systolic blood pressure and cancer mortality in an elderly population. Am J Epidemiol. 1984;120(4): 550-558.
64. Hamet P. Cancer and hypertension. An unresolved issue. Hypertension. 1996;28(3):321-324.
65. Wannamethee G, Shaper AG. Blood pressure and cancer in middle-aged British men. Int J Epidemiol. 1996;25(1):22-31.
66. Calle EE, Thun MJ. Obesity and cancer. Oncogene. 2004;23(38): 6365-6378.
67. Kannel WB, Brand N, Skinner JJ Jr, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Int Med. 1967;67(1):48-59.
68. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343(18): 1305-1311.
69. Swales JD. Meta analysis as a guide to clinical practice. J Hypertens Suppl. 1993;11(5):S59-S63.
70. US Food and Drug Administration (FDA). FDA drug safety communication: ongoing safety review of the angiotensin receptor blockers and cancer [web page on the Internet]. Rockville, MD: 2010 [updated February 6, 2011]. Available from: http://www.fda.gov/Drugs/DrugSafety/Post marketDrugSafetyInformationforPatientsand/ ucm218845.htm. Accessed September 1, 2011.